Title: Protecting Reproductive Freedom Act
Policy area: Health

Summary:
Protecting Reproductive Freedom Act
This bill prohibits states from restricting mifepristone or misoprostol that is approved for medical abortion from being sent across state lines or from being prescribed by telehealth. States are also prohibited from establishing in-person dispensing requirements.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8976 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 8976

      To preempt State restrictions on dispensing mifepristone or 
                  misoprostol, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 22, 2022

Mr. Ryan of New York introduced the following bill; which was referred 
                to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
      To preempt State restrictions on dispensing mifepristone or 
                  misoprostol, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Protecting Reproductive Freedom 
Act''.

SEC. 2. PREEMPTION OF STATE RESTRICTIONS ON DISPENSING MIFEPRISTONE AND 
              MISOPROSTOL.

    No State may establish, implement, or enforce--
            (1) any prohibition or restriction on shipping or sending 
        mifepristone or misoprostol across State lines;
            (2) any requirement that mifepristone or misoprostol be 
        dispensed by a health care practitioner in person; or
            (3) any prohibition or restriction on prescribing or 
        dispensing mifepristone or misoprostol by means of telehealth.

SEC. 3. REPORT.

    Not later than 30 days after the date of enactment of this Act, the 
Secretary of Health and Human Services, acting through the Commissioner 
of Food and Drugs, shall submit a report to the Congress on ways to 
expand access to abortion medication.

SEC. 4. DEFINITIONS.

    In this Act:
            (1) The term ``mifepristone'' means mifepristone that is--
                    (A) approved under subsection (c) or (j) of section 
                505 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355);
                    (B) indicated for medical abortion; and
                    (C) subject to a risk evaluation and mitigation 
                strategy under section 505-1 of the Federal Food, Drug, 
                and Cosmetic Act (21 U.S.C. 355-1).
            (2) The term ``misoprostol'' means misoprostol that is--
                    (A) approved under subsection (c) or (j) of section 
                505 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355);
                    (B) indicated for medical abortion; and
                    (C) subject to a risk evaluation and mitigation 
                strategy under section 505-1 of the Federal Food, Drug, 
                and Cosmetic Act (21 U.S.C. 355-1).
                                 <all>